Urologic Oncology-Seminars and Original Investigations

Article	Citations
Urinary biomarkers in bladder cancer: A review of the current landscape and future directions	96
Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database	73
Mutations in renal cell carcinoma	49
Reconsideration of pelvic floor muscle training to prevent and treat incontinence after radical prostatectomy	44
Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor	41
Papillary renal cell carcinoma: Review	36
The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients	34
Investigating the association between the urinary microbiome and bladder cancer: An exploratory study	33
Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy	32
Prognostic value of preoperative blood-based biomarkers in upper tract urothelial carcinoma treated with nephroureterectomy: A systematic review and meta-analysis	29
Non-muscle-invasive bladder cancer: An overview of potential new treatment options	29
Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: Are they clonally related? A systematic review	29
Systematic review and meta-analysis comparing cognitive vs. image-guided fusion prostate biopsy for the detection of prostate cancer	28
Role of miRNAs in prostate cancer: Do we really know everything?	27
Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer	27
Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer	26
Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?	26
Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review	26
Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis	25
Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer	24
Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study	23
Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma	23
Mutational landscape of non-muscle-invasive bladder cancer	23
Treatment of non-metastatic castration resistant prostate cancer in 2020: What is the best?	23
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients	22

Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer	22
Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy	22
Repurposing metformin as anticancer drug: Randomized controlled trial in advanced prostate cancer (MANSMED)	21
Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer	21
Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study	21
Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer	21
Testis-sparing surgery and scrotal violation for testicular masses suspicious for malignancy: A systematic review and meta-analysis	21
Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer	21
Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study	20
Toward noninvasive follow-up of low-risk bladder cancer – Rationale and concept of the UroFollow trial*	20
Urologic oncology practice during COVID-19 pandemic: A systematic review on what can be deferrable vs. nondeferrable	20
BCG infection (BCGitis) following intravesical instillation for bladder cancer and time interval between treatment and presentation: A systematic review	19
Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer	19
Serum and urine biomarkers for detecting clinically significant prostate cancer	19
Prognostic value of preoperative albumin-to-fibrinogen ratio (AFR) in patients with bladder cancer treated with radical cystectomy	19
Prospective multicentre study using high intensity focused ultrasound (HIFU) for the focal treatment of prostate cancer: Safety outcomes and complications	18
Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer	18
A national cross-sectional survey of financial toxicity among bladder cancer patients	18
Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience	18
Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review	18
Multicenter analysis of clinical and MRI characteristics associated with detecting clinically significant prostate cancer in PI-RADS (v2.0) category 3 lesions	18
PI-RADS 3 lesions: Does the association of the lesion volume with the prostate-specific antigen density matter in the diagnosis of clinically significant prostate cancer?	18
MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass	18
Telemedicine in management of genitourinary malignancies: Patient and physician perspectives	18
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02	18
The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison	17
Pseudouridine as a novel biomarker in prostate cancer	17
Incident testicular cancer in relation to using marijuana and smoking tobacco: A systematic review and meta-analysis of epidemiologic studies	17
Prospective Validation of Clinical Usefulness of a Novel mRNA-based Urine Test (Xpert® Bladder Cancer Monitor) for surveillance in Non Muscle Invasive Bladder Cancer	17
Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus	17
Anxiety, depression and urological cancer outcomes: A systematic review	17
Adult genitourinary sarcoma: A population-based analysis of clinical characteristics and survival	16
Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma	16
Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder	16
Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma	16
Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis	16
Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BC	16
Clinical value of 18FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer	16
Pro-inflammatory cytokines and chemokines initiate multiple prostate cancer biologic pathways of cellular proliferation, heterogeneity and metastasis in a racially diverse population and underlie the	16
Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab	15
Nuclear magnetic resonance spectroscopy of human body fluids and in vivo magnetic resonance spectroscopy: Potential role in the diagnosis and management of prostate cancer	15
Can preoperative renal mass biopsy change clinical practice and reduce surgical intervention for small renal masses?	15
Impact of the controlling nutritional status (CONUT) score on perioperative morbidity and oncological outcomes in patients with bladder cancer treated with radical cystectomy	15
Referral pattern for urologic malignancies before and during the COVID-19 pandemic	15
Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center	15
Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer	15
Microtubule-associated protein tau (MAPT) is a promising independent prognostic marker and tumor suppressive protein in clear cell renal cell carcinoma	15
Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era	15
Association of heavy metals and trace elements in renal cell carcinoma: A case-controlled study	15
Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors	15

Urologic oncology surgery during COVID-19: a rapid review of current triage guidance documents	14
Prognostic nutritional index and prognosis in renal cell carcinoma: A systematic review and meta-analysis	14
Partial orchiectomy: The Princess Margaret cancer centre experience	14
Sarcopenia as a predictor of postoperative outcomes after urologic oncology surgery: A systematic review and meta-analysis	14
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma	14
Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era	14
Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer	14
Robotic-assisted tumor enucleation versus standard margin partial nephrectomy: Perioperative, renal functional, and oncologic outcomes for low and intermediate complexity renal masses	14
Clinicopathological significance and prognostic value of cancer-associated fibroblasts in prostate cancer patients	14
Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia	14
Contemporary trends in percutaneous renal mass biopsy utilization in the United States	13
Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis	13
Risk stratification metrics for bladder cancer: Comprehensive Geriatric Assessments	13
Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: A single centre, prosp	13
C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab	13
Acrolein contributes to urothelial carcinomas in patients with chronic kidney disease	13
Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy	13
Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients	13
Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma	13
Upstaging to pT3a disease in patients undergoing robotic partial nephrectomy for cT1 kidney cancer: Outcomes and predictors from a multi-institutional dataset	12
Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays	12
Impact of systemic Immune–inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer	12
Bioptic intraprostatic chronic inflammation predicts adverse pathology at radical prostatectomy in patients with low-grade prostate cancer	12
The use of 29 MHz transrectal micro-ultrasound to stratify the prostate cancer risk in patients with PI-RADS III lesions at multiparametric MRI: A single institutional analysis	12
Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer	12
A novel nomogram predicting lymph node invasion among patients with prostate cancer: The importance of extracapsular extension at multiparametric magnetic resonance imaging	12
Assessments of frailty in bladder cancer	12
Management of urologic cancers during the pandemic and potential impact of treatment deferrals on outcomes	12
PI-RADS score is associated with biochemical control and distant metastasis in men with intermediate-risk and high-risk prostate cancer treated with radiation therapy	12
Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer	12
Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study	12
Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial	12
A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer	12
Artificial intelligence in urological oncology: An update and future applications	12
Inguinal lymph node dissection in the era of minimally invasive surgical technology	12
Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells	12
Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy	12
A simplified nomogram to assess risk of bladder cancer in patients with a new diagnosis of microscopic hematuria	12
Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members	12
External validation of the Martini nomogram for prediction of side-specific extraprostatic extension of prostate cancer in patients undergoing robot-assisted radical prostatectomy	12
Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review	12
Psychological distress associated with active surveillance in patients younger than 70 with a small renal mass	12
Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma	12
Interpreting nephrometry scores with three-dimensional virtual modelling for better planning of robotic partial nephrectomy and predicting complications	12
Multicenter transperineal MRI-TRUS fusion guided outpatient clinic prostate biopsies under local anesthesia	12
The robotic approach improves the outcomes of ERAS protocol after radical cystectomy: A prospective case-control analysis	11
Assessing patient risk from cancer and COVID-19: Managing patient distress	11
High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer –Results from a prospective pilot study using a 37 gene panel	11
A machine learning approach to predict progression on active surveillance for prostate cancer	11
Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer	11
The effect of metastasectomy on overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis	11
Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA)	11
Functional and oncological outcome of percutaneous cryoablation versus laparoscopic partial nephrectomy for clinical T1 renal tumors: A propensity score-matched analysis	11
Use of beta-blocker types and risk of incident prostate cancer in a multiethnic population	11
Second line salvage systemic therapy for advanced penile cancer	11
The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort	11
A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade	11
Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma	11
A systematic review and meta-analysis of magnetic resonance imaging and ultrasound guided fusion biopsy of prostate for cancer detection—Comparing transrectal with transperineal approaches	11
Safety and side effects of transperineal prostate biopsy without antibiotic prophylaxis	11
Examining the association of health literacy and numeracy with prostate-related knowledge and prostate cancer treatment regret	11
Effect of frailty and comorbidity on surgical contraindication in patients with localized prostate cancer (FRART-PC Study)	11
The role of Tc-99m MIBI scintigraphy in clinical T1 renal mass assessment: Does it have a real benefit?	11
Definition of high-risk prostate cancer impacts oncological outcomes after radical prostatectomy	11
Ten-year disease progression and mortality rates in men who experience biochemical recurrence versus persistence after radical prostatectomy and undergo salvage radiation therapy: A post-hoc analysis	10
Long term outcomes of ureteroscopic management of upper tract urothelial carcinoma	10
Estimating the rate and reasons of clinical trial failure in urologic oncology	10
External validation of the Briganti nomogram predicting lymph node invasion in patients with intermediate and high-risk prostate cancer diagnosed with magnetic resonance imaging-targeted and systemati	10
Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start	10
A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer	10
The effect of urinary diversion on long-term kidney function after cystectomy	10
The stanford prostate cancer calculator: Development and external validation of online nomograms incorporating PIRADS scores to predict clinically significant prostate cancer	10
Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma	10
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high–grade non-muscle-invasive urothelial bladder cancer	10
Implementation of a nonopioid protocol following robot-assisted radical cystectomy with intracorporeal urinary diversion	10
Disparities in precision medicine—Examining germline genetic counseling and testing patterns among men with prostate cancer	10
Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma	10
Nutrition risk and assessment process in patients with bladder cancer undergoing radical cystectomy	10
Post-translational modifications in bladder cancer: Expanding the tumor target repertoire	10
Postoperative membranous urethral length is the single most important surgical factor predicting recovery of postoperative urinary continence	10

Risk factors and reasons for reoperation after radical cystectomy	10
Prostatic-specific antigen density behavior according to multiparametric magnetic resonance imaging result	10
Combined clinical characteristics and multiparametric MRI parameters for prediction of cribriform morphology in intermediate-risk prostate cancer patients	10
The role of multiparametric MRI in active surveillance for low-risk prostate cancer: The ROMAS randomized controlled trial	10
Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review	10
Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for 18F-fluciclovine-PET/CT in delineating sites of recurrence and identifying patients with oligometasta	10
Nephroureterectomy vs. segmental ureterectomy of clinically localized, high-grade, urothelial carcinoma of the ureter: Practice patterns and outcomes	10
Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus	9
Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy	9
Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States	9
Management of bone and metabolic effects of androgen deprivation therapy	9
The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?	9
The utility of intraoperative contrast-enhanced ultrasound in detecting residual disease after focal HIFU for localized prostate cancer	9
Risk stratification for bladder cancer: Biomarkers of inflammation and immune activation	9
Metastasis-directed radiation therapy after radical cystectomy for bladder cancer	9
Utilization of renal mass biopsy in patients with localized renal cell carcinoma: A population-based study utilizing the National Cancer Database	9
An evaluation of trends in the representation of patients by age, sex, and diverse race/ethnic groups in bladder and kidney cancer clinical trials	9
Diagnostic accuracy of vesical imaging-reporting and data system (VI-RADS) in suspected muscle invasive bladder cancer: A systematic review and diagnostic meta-analysis	9
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction cours	9
TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer	9
The role of 18F-FDG PET/CT scan compared to CT-scan alone for lymph node staging before radical cystectomy in patients with bladder cancer	9
Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration	9
Critical shortage in BCG immunotherapy: How did we get here and where will it take us?	9
External validation of the VENUSS prognostic model to predict recurrence after surgery in non-metastatic papillary renal cell carcinoma: A multi-institutional analysis	9
PAK1 expression determines poor prognosis and immune evasion in metastatic renal cell carcinoma patients	9
Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer	9
Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy	9
Can repeat biopsy be skipped after initial complete resection of T1 bladder cancer? The role of a novel urinary mRNA biomarker	9
Effects of “real life” prostate MRI inter-observer variability on total needle samples and indication for biopsy	9
Impact of body size and body composition on bladder cancer outcomes: Risk stratification and opportunity for novel interventions	9
MMPs, tyrosine kinase signaling and extracellular matrix proteolysis in kidney cancer	9
Long term outcomes for patients with von Hippel-Lindau and Pheochromocytoma: defining the role of active surveillance	9
The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma.	8
Oncologic outcomes of laparoscopic radical nephroureterectomy in conjunction with template-based lymph node dissection: An extended follow-up study	8
Histone-dependent PARP-1 inhibitors: A novel therapeutic modality for the treatment of prostate and renal cancers	8
Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targete	8
Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling	8
Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?	8
Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non–muscle-invasive bladder cancer after BCG failure	8
Do patients with a PI-RADS 5 lesion identified on magnetic resonance imaging require systematic biopsy in addition to targeted biopsy?	8
The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis	8
Prognostic significance of extent of venous tumor thrombus in patients with non-metastatic renal cell carcinoma: Results from a Canadian multi-institutional collaborative	8
Metabolomics informs common patterns of molecular dysfunction across histologies of renal cell carcinoma	8
The impact of very high initial PSA on oncological outcomes after radical prostatectomy for clinically localized prostate cancer	8
Bladder cancer risk stratification using a urinary mRNA biomarker panel – A path towards cystoscopy triaging	8
Oncological control following partial gland ablation for intermediate-risk prostate cancer	8
Comprehensive genomic profiling of histologic subtypes of urethral carcinomas	8
Outcomes of perineal urethrostomy for penile cancer: A 20-year international multicenter experience	8
Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy	8
Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era?	8
MiR-486-5p enhances cisplatin sensitivity of human muscle-invasive bladder cancer cells by induction of apoptosis and down-regulation of metastatic genes	8
A nomogram incorporating PD-L1, NLR, and clinicopathologic features to predict inguinal lymph node metastasis in penile squamous cell carcinoma	8
Free-indocyanine green-guided pelvic lymph node dissection during radical prostatectomy	8
Outcomes of palliative cystectomy in patients with locally advanced pT4 bladder cancer	8
Is partial nephrectomy safe and effective in the setting of frail comorbid patients affected by renal cell carcinoma? Insights from the RECORD 2 multicentre prospective study	8
Adjuvant radiation compares favorably to chemotherapy in patients with carcinoma penis and nodal positivity restricted to groin	8
Comparison of the prognosis of primary vs. progressive muscle invasive bladder cancer after radical cystectomy: Results from a large multicenter study	8
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab	8
Organ preserving radiation strategies for penile cancer	8
Efficacy and toxicity outcomes of elderly castrate-resistant prostate cancer patients treated with docetaxel—A pooled analysis of 3 randomized studies	8
Management of prostate cancer after holmium laser enucleation of the prostate	8
A novel nomogram combined PIRADS v2 and neutrophil-to-lymphocyte ratio to predict the risk of clinically significant prostate cancer in men with PSA < 10 ng/ml at first biopsy	8
Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer	8
Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors	8
MicroRNA profile in stage I clear cell renal cell carcinoma predicts progression to metastatic disease	8
Primary Ta high grade bladder tumors: Determination of the risk of progression	8
How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series	8
“Real-world” outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma	8
Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy	8
Locoregional recurrence after cystectomy in muscle invasive bladder cancer: Implications for adjuvant radiotherapy	8
The role of perilesional and multiparametric resonance imaging-targeted biopsies to reduce the risk of upgrading at radical prostatectomy pathology: A retrospective monocentric study	8
Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non–muscle invasive bladder cancer during BCG shortage	7
Simultaneous versus staged partial nephrectomies for bilateral synchronous solid renal masses	7
Prognostic value of the SPOP mutant genomic subclass in prostate cancer	7
Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large m	7
Management of penile cancer patients during the COVID-19 pandemic: An eUROGEN accelerated Delphi consensus study	7
PD-1 topographically defines distinct T cell subpopulations in urothelial cell carcinoma of the bladder and predicts patient survival	7
Defining radical cystectomy using the ICD-10 procedure coding system	7
Systemic therapy in bladder preservation	7
Prognostic value of the fluctuation in the neutrophil–lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma	7
Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma	7
Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT)	7
Race, ethnicity, and gender reporting in North American clinical trials for BCG-unresponsive non-muscle invasive bladder cancer	7
Multidisciplinary Approach for the Management of Penoscrotal Extramammary Paget's disease –An eUROGEN study	7
Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors	7
Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study	7
Comparison of renal function after open radical cystectomy, extracorporeal robot assisted radical cystectomy, and intracorporeal robot assisted radical cystectomy	7
Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients	7
Medium Term Outcomes of Focal Cryoablation for Intermediate and High Risk Prostate Cancer: MRI and PSA are Not Predictive of Residual or Recurrent Disease	7
Cell membrane and nuclear expression of programmed death ligand-1 in prostate needle biopsy tissue in prostate cancer patients undergoing primary radiation therapy	7
The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancer	7
Renal cell carcinoma with tumor thrombus: A review of relevant anatomy and surgical techniques for the general urologist	7
Association of Bacillus Calmette–Guerin shortages with bladder cancer recurrence: A single-center retrospective study	7
Predictors of adequate lymph node dissection in patients with non–muscle invasive bladder cancer undergoing radical cystectomy and effect on survival	7
Statin use and risk of prostate cancer biochemical recurrence after radical prostatectomy	7